Pulmonology AdvisorEpigenetic IgE Score May Predict Childhood Respiratory Morbidity

⚠️ Small Study / Early Comparative Evidence
A 107-CpG DNAm-IgE score derived in infancy was associated with recurrent wheezing by age 3 in meta-analyses across three pediatric cohorts. The score reflects early-life immune programming beyond measured serum IgE.

Clinical Considerations

• One SD of DNAm-IgE residuals was associated with recurrent wheezing (OR 1.33; 95% CI 1.11-1.60); one SD of total IgE was associated with asthma at age 6 (OR 1.45).
• The most weighted CpGs mapped to genes tied to inflammatory regulation and airway smooth-muscle responses, including ZNF141, ARHGEF1, and LACTBL1.
• Validation correlations varied substantially across cohorts (R=0.502 in MARC-35 vs R=0.132 in BBC), reflecting differences in biofluid source, population, and risk profile.
• Authors emphasized the score’s prognostic utility has not been established and may not capture broader mechanisms of early-life asthma.

Practice Applications

• Recognize epigenetic IgE scoring as an emerging area of investigation, not a clinically actionable test.
• Interpret as a biomarker of early-life immune programming rather than a diagnostic for future wheezing or asthma.
• Avoid discussing methylation-based risk scores with families outside research contexts.
• Monitor further validation in larger, more diverse pediatric cohorts before any clinical application.

More in Asthma